Ardelyx Suffers Legal Setback as Appeals Court Confirms XPHOZAH in Medicare Bundle
Ardelyx shares fell after losing a court case on Xphozah Medicare coverage, moving drug into bundled payments, hurting revenue outlook.
Ardelyx shares fell after losing a court case on Xphozah Medicare coverage, moving drug into bundled payments, hurting revenue outlook.
Decision due Aug 5, 2026. Potential 2026–27 launch.
AI-powered 60-second scans could transform preventive healthcare.
TAVR is Edwards’ main business. New CMS rules could boost sales and help it take market share from Medtronic and Boston Scientific.
Medicare plans drug price cuts from 2029, hitting pharma stocks, but long-term impact may be limited by legal and market protections.
Hunterbrook report accuses Ensign Group of understaffing, gaming metrics, and patient neglect.